New test

Tears don't lie – they may even help diagnose Parkinson’s

Tears may hold clues to whether someone has Parkinson’s disease, according to a preliminary study released that will be presented at the American Academy of Neurology’s 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.

Photo
Source: Pixabay/cherylholt

“We believe our research is the first to show that tears may be a reliable, inexpensive and noninvasive biological marker of Parkinson’s disease,” said study author Mark Lew, MD, of the Keck School of Medicine of the University of Southern California in Los Angeles and a Fellow of the American Academy of Neurology. Lew says the research team investigated tears because they contain various proteins produced by the secretory cells of the tear gland, which is stimulated by nerves to secrete these proteins into tears. Because Parkinson’s can affect nerve function outside of the brain, the research team hypothesized that any change in nerve function may be seen in the protein levels in tears.

Source: Pixabay/Bella67

Because the Parkinson’s disease process can begin years or decades before symptoms appear, a biological marker like this could be useful in diagnosing, or even treating, the disease earlier

Mark Lew

For the study, tear samples from 55 people with Parkinson’s were compared to tear samples from 27 people who did not have Parkinson’s but who were the same age and gender. Tears were analyzed for the levels of four proteins. Researchers found differences in the levels of a particular protein, alpha-synuclein, in the tears of people with Parkinson’s compared to controls. Additionally, levels of another form of alpha-synuclein, oligomeric alpha-synuclein, which is alpha-synuclein that has formed aggregates that are implicated in nerve damage in Parkinson’s, were also significantly different compared to controls. It is also possible that the tear gland secretory cells themselves produce these different forms of alpha-synuclein that can be directly secreted into tears.

Total levels of alpha-synuclein were decreased in people with Parkinson’s, with an average of 423 picograms of that protein per milligram (pg/mg) compared to 704 pg/mg in people without Parkinson’s. But levels of oligomeric alpha-synuclein were increased in people with Parkinson’s, with an average of 1.45 nanograms per milligram of tear protein (ng/mg) compared to 0.27 ng/mg in people without the disease. A picogram is 1,000 times smaller than a nanogram. “Knowing that something as simple as tears could help neurologists differentiate between people who have Parkinson’s disease and those who don’t in a noninvasive manner is exciting,” said Lew. “And because the Parkinson’s disease process can begin years or decades before symptoms appear, a biological marker like this could be useful in diagnosing, or even treating, the disease earlier.” 

More research now needs to be done in larger groups of people to investigate whether these protein changes can be detected in tears in the earliest stages of the disease, before symptoms start.

The study was supported by The Michael J. Fox Foundation for Parkinson’s Research and the Plotkin Foundation.


Source: American Academy of Neurology (AAN)

23.02.2018

More on the subject:
Read all latest stories

Related articles

Photo

Preventive potential

Tell-tale signs of heightened stroke risk may appear up to 10 years earlier

The tell-tale signs of a person’s susceptibility to a stroke may appear up to 10 years before the event, suggests research published online in the Journal of Neurology Neurosurgery &…

Photo

More attempts, worse outcomes

Removing blood clots after stroke: Why the first try counts

After a stroke, doctors can try to remove clots in blood vessels to keep blood flowing freely to the brain. But even though most of these procedures are successful, less than half of people have a…

Photo

In different medical fields

Women and men are each underrepresented in clinical trials

A study showed that women are underrepresented in oncology, neurology, immunology, cardiology, hematology; whereas men underrepresented in trials related to mental health, musculoskeletal disease and…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter